$EYPT 8-K SEC Filings

Filed On	Filing
19 Oct 2026	8-K: Results of Operations and Financial Condition; Cost Associated with Exit or Disposal Activities +1 more WATERTOWN, Mass., October 19, 2026 (GLOBE NEWSWIRE) – EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today anno...
19 Oct 2026	8-K: Other Events – LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –
10 Sep 2026	8-K: Other Events LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses \| September 2026 Exhibit 99.1
17 Aug 2026	8-K: Other Events
05 Aug 2026	8-K: Results of Operations and Financial Condition
30 Jul 2026	8-K: Other Events
17 Jul 2026	8-K: Entry into a Material Definitive Agreement
22 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
14 May 2026	8-K: Other Events
06 May 2026	8-K: Results of Operations and Financial Condition
13 Apr 2026	8-K: Other Events
20 Mar 2026	8-K: Regulation FD Disclosure
04 Mar 2026	8-K: Results of Operations and Financial Condition
02 Mar 2026	8-K: Other Events
07 Jan 2026	8-K: Results of Operations and Financial Condition
08 Dec 2025	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
19 Nov 2025	8-K: Other Events
06 Nov 2025	8-K: Other Events
05 Nov 2025	8-K: Results of Operations and Financial Condition
17 Oct 2025	8-K: Entry into a Material Definitive Agreement; Other Events

Comments